RxDoctor Payments Data

Jeremy Parker, MD

Cardiovascular Disease · Anderson, SCNPI 1669676946

Payments from drug & device makers

$7,388in general payments, 2019–2025

Across 447 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$854
  • Boston Scientific$548
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$521
  • AstraZeneca$503
  • Amgen$419
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$7,30199%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,388 in reported general payments places this provider in the 65th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$213,401
Medicare patients
2,414
Services billed
4,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban350$333,380
EntrestoSacubitril/Valsartan110$129,746
FarxigaDapagliflozin Propanediol85$73,347
Repatha SureclickEvolocumab64$51,421
JardianceEmpagliflozin51$47,641
XareltoRivaroxaban29$34,687
Ranolazine ErRanolazine80$6,697
Praluent PenAlirocumab12$5,728
Diltiazem 12hr ErDiltiazem Hcl17$5,687
Ezetimibe155$5,167
Atorvastatin Calcium386$3,719
Metoprolol Succinate293$3,489
Rosuvastatin Calcium226$2,466
Valsartan88$2,217
Propafenone Hcl ErPropafenone Hcl16$1,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$321$333,380350 claims
NovartisEntresto$1,453$129,746110 claims
AstraZenecaFarxiga$503$73,34785 claims
Boehringer IngelheimJardiance$276$47,64151 claims
Johnson & JohnsonXarelto$854$34,68729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →